GSK plc Share Price Deutsche Boerse AG

Equities

GS71

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Tradegate 07:51:10 23/05/2024 BST 5-day change 1st Jan Change
20.98 EUR +0.62% Intraday chart for GSK plc +0.48% +24.97%

Financials

Sales 2024 * 31.63B 40.24B 37.17B 3,163B Sales 2025 * 33.58B 42.73B 39.47B 3,358B Capitalization 72.94B 92.79B 85.72B 7,294B
Net income 2024 * 5.54B 7.05B 6.52B 554B Net income 2025 * 6.49B 8.26B 7.63B 649B EV / Sales 2024 * 2.69 x
Net Debt 2024 * 12.29B 15.63B 14.44B 1,229B Net Debt 2025 * 9.07B 11.54B 10.66B 907B EV / Sales 2025 * 2.44 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
11.2 x
Employees 70,212
Yield 2024 *
3.41%
Yield 2025 *
3.54%
Free-Float 94.54%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.62%
1 week+0.48%
Current month+7.47%
1 month+10.76%
3 months+7.81%
6 months+28.86%
Current year+24.97%
More quotes
1 week
20.38
Extreme 20.38
21.09
1 month
18.70
Extreme 18.7
21.49
Current year
16.48
Extreme 16.482
21.49
1 year
15.24
Extreme 15.242
21.49
3 years
14.62
Extreme 14.62
27.13
5 years
14.62
Extreme 14.62
27.52
10 years
14.62
Extreme 14.62
28.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 30/04/10
Director of Finance/CFO 62 30/04/23
Compliance Officer - 31/07/95
Members of the board TitleAgeSince
Director of Finance/CFO 62 30/04/23
Chairman 66 31/08/19
Director/Board Member 62 31/12/17
More insiders
Date Price Change Volume
22/05/24 20.85 +2.16% 0
21/05/24 20.41 -0.92% 992
20/05/24 20.6 -2.32% 0
17/05/24 21.09 +2.78% 2
16/05/24 20.52 -1.11% 6,900

Delayed Quote Deutsche Boerse AG, May 22, 2024 at 08:50 pm

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.88 GBP
Average target price
20.32 GBP
Spread / Average Target
+13.63%
Consensus